Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis
Clinical & Experimental Allergy · 2025-09 · 55 (9) · 755-772
DOI: 10.1111/cea.70125 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 02.08.2025. Verfasst von Yunha Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The aim of this study is to evaluate the effectiveness and safety of JAK inhibitors in patients with moderate to severe atopic dermatitis by performing a systematic review and meta‐analysis using data from studies in real‐world settings.
Design
Systematic review and meta‐analysis. Pooled estimates for effectiveness and safety were assessed using the Freeman–Tukey Double ArcSine method. Statistical heterogeneity was assessed using I 2 statistics. A random‐effects model (DerSimonian‐Laird method) was applied to consider the heterogeneity within and between studies and to give a more conservative estimate. The study quality assessment tools developed by the National Heart, Lung, and Blood Institute were used. Data Source Relevant studies were searched in March 2025 using four databases: PubMed, Embase, Scopus, and Web of Science. Eligibility Criteria Studies evaluating the effectiveness or safety of systemic JAK inhibitors among patients with moderate to severe atopic dermatitis in a real‐world setting were included.
Results
A total of 50 studies were included in this review. Regarding their effectiveness, the pooled estimates with a 95% CI of Eczema Area and Severity Index (EASI)‐75 were 44% (34%–55%), 45% (28%–62%), 59% (51%–66%), 73% (64%–81%), 70% (57%–81%), and 86% (72%–96%) at 4, 8, 12, 16, 24, and 52 weeks. For safety, the most common adverse events were acne (16%), followed by increased creatine phosphokinase levels (13%) and increased lipids (12%).
Conclusion
Our meta‐analysis of JAK inhibitors in patients with atopic dermatitis demonstrated that the overall outcomes from real‐world settings are comparable to those from clinical trials. Systematic Review Registration Protocol Registration: PROSPERO CRD42024569258.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Yunha Kim, Gayeong Seo, Jacob J E Koopman, Jeong Yee
Zitieren
APA
Kim, Y., Seo, G., Koopman, J. J. E., & Yee, J. (2025). Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Clinical & Experimental Allergy, 55(9), 755-772. https://doi.org/10.1111/cea.70125
Vancouver
Kim Y, Seo G, Koopman JJE, Yee J. Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Clinical & Experimental Allergy. 2025;55(9):755-772. doi:10.1111/cea.70125
BibTeX
@article{Kim2025,
author = {Kim, Yunha and Seo, Gayeong and Koopman, Jacob J E and Yee, Jeong},
title = {Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis},
journal = {Clinical & Experimental Allergy},
year = {2025},
volume = {55},
number = {9},
pages = {755--772},
doi = {10.1111/cea.70125}
}
EUVIMED